Incyte (INCY)
Health Care · Oncology and immunology therapeutics
A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating substantial cash flow.
What Incyte does
Incyte is a biopharmaceutical company that discovers, develops, and commercializes targeted small-molecule therapies. The company's lead product, JAKAFI (ruxolitinib), is a JAK inhibitor approved for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, marketed internationally as JAKAVI. Incyte also commercializes several additional approved products including ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI, OPZELURA, ZYNYZ, and NIKTIMVO, while receiving royalties from licensed partners (Novartis, Eli Lilly) for globally marketed products.
Themes: ["JAK pathway inhibition","blood cancers / myeloproliferative neoplasms","hematologic malignancies","immunology / GVHD","specialty oncology","rare disease focus"]
Fundamentals
- Price$118.52 as of 2026-07-09 close
- Market cap$23.5B as of 2026-07-10
- 1-year return+73.3% as of 2026-07-09 close
- P/E16.44 as of 2026-07-10
- Net margin+26.7% as of 2026-07-10
- Gross margin+93.0% as of 2026-07-10
- ROE+29.2% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Revenue growth (YoY)+21.5% as of 2026-07-10
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta0.77 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on JAKAFI revenues which is anticipated to decline upon patent expiration in 2028","Pricing and reimbursement pressure from government health systems and third-party payors pursuing drug cost management initiatives","Reliance on third-party manufacturers for sufficient quality production of key products and third-party collaborators for international commercialization"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.